Results 21 to 30 of about 11,390 (145)
Nature Communications, 2016 Fulvestrant degrades the oestrogen receptor. Here, the authors report on a clinical trial using fulvestrant and show that mutations in the oestrogen receptor alpha gene are prevalent in circulating tumour DNA and do not influence the clinical outcome of ...
Jill M. Spoerke +15 more
doaj +1 more source
Journal of Translational Medicine, 2019 Background Among breast cancer (BC) patients, near 40% are post-menopause, and 70%–80% are hormone receptor (HR)-positive. About 30%–40% BC patients who are diagnosed as invasive carcinoma HR-positive BC would eventually develop metastatic breast cancers.
Jingyu Liu +7 more
doaj +1 more source
Breast Cancer Research, 2021 Background Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lacking. This unmet need is mainly due
Kamila Kaminska +16 more
doaj +1 more source
Journal of Pharmacological Sciences, 2015 Previous studies demonstrated that sulfate conjugation is involved in the metabolism of three commonly used breast cancer drugs, tamoxifen, raloxifene and fulvestrant.
Ying Hui +7 more
doaj +1 more source
Nature CommunicationsIn the global CAPItello-291 randomized phase 3 study (NCT04305496) in patients with hormone receptor-positive/HER2-negative advanced breast cancer and progression during/after aromatase inhibitor treatment, capivasertib–fulvestrant significantly improved
Xichun Hu +23 more
doaj +1 more source
Fulvestrant: pharmacokinetics and pharmacology [PDF]
British Journal of Cancer, 2004 Fulvestrant is a new type of oestrogen receptor (ER) antagonist with no agonist activity and a novel pharmacological profile. Fulvestrant has been shown to significantly reduce cellular levels of the ER and progesterone receptor in both preclinical studies and in clinical trials of postmenopausal women with primary breast cancer. This paper reviews the
Robertson, J F R, Harrison, M
openaire +2 more sources
All‐PEG‐Like Block Copolymers Self‐Assemble into Stealth Nanocarriers for Drug Delivery
Advanced Science, EarlyView.Self‐assembling nanoparticles composed entirely of POEGMA are engineered by exploiting side‐chain–dependent amphiphilicity and tunable thermoresponsive behavior. These single‐material nanocarriers encapsulate diverse hydrophobic drugs with high efficiency, retain therapeutic activity, improve in vivo efficacy, and evade anti‐PEG antibodies.
Parul Sirohi +15 more
wiley +1 more source
Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients. [PDF]
PLoS ONE, 2014 Fulvestrant is a selective estrogen receptor antagonist. Based on the measured growth inhibition of 60 human cancer cell lines (NCI60) in the presence of fulvestrant, as well as the baseline gene expression of the 60 cell lines, a gene expression score ...
Steen Knudsen +7 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader. Methods This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants.
Hechuan Wang +7 more
wiley +1 more source
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
npj Breast Cancer, 2023 This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2, ER+/HER2− measurable or evaluable metastatic BC. Prior fulvestrant was allowed.
Anthony D. Elias +22 more
doaj +1 more source